FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313313072> ?p ?o ?g. }

• W4313313072 endingPage "168" @default.
• W4313313072 startingPage "157" @default.
• W4313313072 abstract "ConspectusSARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The unprecedented disruption of social life and public health caused by COVID-19 calls for fast-track development of diagnostic kits, vaccines, and antiviral drugs. Small molecule antivirals are essential complements of vaccines and can be used for the treatment of SARS-CoV-2 infections. Currently, there are three FDA-approved antiviral drugs, remdesivir, molnupiravir, and paxlovid. Given the moderate clinical efficacy of remdesivir and molnupiravir, the drug–drug interaction of paxlovid, and the emergence of SARS-CoV-2 variants with potential drug-resistant mutations, there is a pressing need for additional antivirals to combat current and future coronavirus outbreaks.In this Account, we describe our efforts in developing covalent and noncovalent main protease (Mpro) inhibitors and the identification of nirmatrelvir-resistant mutants. We initially discovered GC376, calpain inhibitors II and XII, and boceprevir as dual inhibitors of Mpro and host cathepsin L from a screening of a protease inhibitor library. Given the controversy of targeting cathepsin L, we subsequently shifted the focus to designing Mpro-specific inhibitors. Specifically, guided by the X-ray crystal structures of these initial hits, we designed noncovalent Mpro inhibitors such as Jun8-76-3R that are highly selective toward Mpro over host cathepsin L. Using the same scaffold, we also designed covalent Mpro inhibitors with novel cysteine reactive warheads containing di- and trihaloacetamides, which similarly had high target specificity. In parallel to our drug discovery efforts, we developed the cell-based FlipGFP Mpro assay to characterize the cellular target engagement of our rationally designed Mpro inhibitors. The FlipGFP assay was also applied to validate the structurally disparate Mpro inhibitors reported in the literature. Lastly, we introduce recent progress in identifying naturally occurring Mpro mutants that are resistant to nirmatrelvir from genome mining of the nsp5 sequences deposited in the GISAID database. Collectively, the covalent and noncovalent Mpro inhibitors and the nirmatrelvir-resistant hot spot residues from our studies provide insightful guidance for future work aimed at developing orally bioavailable Mpro inhibitors that do not have overlapping resistance profile with nirmatrelvir." @default.
• W4313313072 created "2023-01-06" @default.
• W4313313072 creator A5038843248 @default.
• W4313313072 creator A5052178405 @default.
• W4313313072 creator A5060065671 @default.
• W4313313072 creator A5070934336 @default.
• W4313313072 creator A5084438338 @default.
• W4313313072 date "2022-12-29" @default.
• W4313313072 modified "2023-10-15" @default.
• W4313313072 title "SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies" @default.
• W4313313072 cites W1985803640 @default.
• W4313313072 cites W2006286994 @default.
• W4313313072 cites W2129577287 @default.
• W4313313072 cites W2316769242 @default.
• W4313313072 cites W2903899730 @default.
• W4313313072 cites W2914616799 @default.
• W4313313072 cites W3005527412 @default.
• W4313313072 cites W3009912996 @default.
• W4313313072 cites W3011701533 @default.
• W4313313072 cites W3014871807 @default.
• W4313313072 cites W3021718590 @default.
• W4313313072 cites W3022435472 @default.
• W4313313072 cites W3032297724 @default.
• W4313313072 cites W3034228022 @default.
• W4313313072 cites W3080596815 @default.
• W4313313072 cites W3081918364 @default.
• W4313313072 cites W3092136311 @default.
• W4313313072 cites W3092541273 @default.
• W4313313072 cites W3093650985 @default.
• W4313313072 cites W3094104502 @default.
• W4313313072 cites W3096967708 @default.
• W4313313072 cites W3097591292 @default.
• W4313313072 cites W3113283058 @default.
• W4313313072 cites W3123245089 @default.
• W4313313072 cites W3126798852 @default.
• W4313313072 cites W3131767541 @default.
• W4313313072 cites W3133536922 @default.
• W4313313072 cites W3134111825 @default.
• W4313313072 cites W3151076337 @default.
• W4313313072 cites W3152703278 @default.
• W4313313072 cites W3159002759 @default.
• W4313313072 cites W3162323249 @default.
• W4313313072 cites W3168783480 @default.
• W4313313072 cites W3180265430 @default.
• W4313313072 cites W3189646261 @default.
• W4313313072 cites W3205127490 @default.
• W4313313072 cites W3208802464 @default.
• W4313313072 cites W3210259768 @default.
• W4313313072 cites W3215590980 @default.
• W4313313072 cites W4200510858 @default.
• W4313313072 cites W4206112304 @default.
• W4313313072 cites W4210535294 @default.
• W4313313072 cites W4210665241 @default.
• W4313313072 cites W4210787373 @default.
• W4313313072 cites W4212949239 @default.
• W4313313072 cites W4220970238 @default.
• W4313313072 cites W4224253542 @default.
• W4313313072 cites W4224928586 @default.
• W4313313072 cites W4225286967 @default.
• W4313313072 cites W4229045071 @default.
• W4313313072 cites W4283730960 @default.
• W4313313072 cites W4285719527 @default.
• W4313313072 cites W4297259300 @default.
• W4313313072 cites W4308683905 @default.
• W4313313072 cites W4385215555 @default.
• W4313313072 doi "https://doi.org/10.1021/acs.accounts.2c00735" @default.
• W4313313072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36580641" @default.
• W4313313072 hasPublicationYear "2022" @default.
• W4313313072 type Work @default.
• W4313313072 citedByCount "20" @default.
• W4313313072 countsByYear W43133130722023 @default.
• W4313313072 crossrefType "journal-article" @default.
• W4313313072 hasAuthorship W4313313072A5038843248 @default.
• W4313313072 hasAuthorship W4313313072A5052178405 @default.
• W4313313072 hasAuthorship W4313313072A5060065671 @default.
• W4313313072 hasAuthorship W4313313072A5070934336 @default.
• W4313313072 hasAuthorship W4313313072A5084438338 @default.
• W4313313072 hasBestOaLocation W43133130721 @default.
• W4313313072 hasConcept C114851261 @default.
• W4313313072 hasConcept C159047783 @default.
• W4313313072 hasConcept C181199279 @default.
• W4313313072 hasConcept C185592680 @default.
• W4313313072 hasConcept C2776714187 @default.
• W4313313072 hasConcept C2777494893 @default.
• W4313313072 hasConcept C2779756493 @default.
• W4313313072 hasConcept C2780035454 @default.
• W4313313072 hasConcept C55493867 @default.
• W4313313072 hasConcept C64903051 @default.
• W4313313072 hasConcept C71924100 @default.
• W4313313072 hasConcept C74187038 @default.
• W4313313072 hasConcept C86803240 @default.
• W4313313072 hasConcept C89423630 @default.
• W4313313072 hasConcept C98274493 @default.
• W4313313072 hasConceptScore W4313313072C114851261 @default.
• W4313313072 hasConceptScore W4313313072C159047783 @default.
• W4313313072 hasConceptScore W4313313072C181199279 @default.
• W4313313072 hasConceptScore W4313313072C185592680 @default.
• W4313313072 hasConceptScore W4313313072C2776714187 @default.

• next